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Abstract: This paper provides the theoretical framework for a case study
that I share with students in my courses. The dialectical theory2 is used to analyze
ethical conundrums pertaining to Genzyme, a successful bio-tech corporation
based in Boston, Massachusetts that manufactures treatments for serious diseases
such as kidney problems, immune diseases, and cancer.3 We discuss questions
such as: is Genzyme acting unethically when averaging extremely high profit
margins on drugs for rare diseases? Is the company taking advantage of the lack of
pharmaceutical choices that patients have when addressing their ailments?
The dialectical theory provides the framework and vocabulary for discussing,
unpacking, and analyzing the complex aspects of this ethics case study. The
students are taught various management strategies for dealing with dialectical
tensions. Moreover, students are encouraged to think objectively and systemically
in order to understand the complexities of ethical decision-making processes.
INTRODUCTION
Players in the pharmaceutical arena are faced with a conundrum: to price
their products to maximize profit or to price their products to maximize consumer
equality. The inflated prices of many drugs like Genzyme’s Cerezyme4 lead many
critics to believe that, more often than not, the profit maximizing option is chosen.5
The ability to focus on profit maximization and the resulting high prices can be
attributed to the fully functioning American free market and the inherently
oligopolistic pharmaceutical industry.6 Other countries, such as Canada, are able
to offer lower prices for their drugs as a result of negotiations between drug
companies and the respective governments.7
Many people accept these sky-high prices and justify them by noting the

2
The dialectical theory examines the interplay of opposites and the way relational and
organizational outcomes, processes, and systems are influenced by the management of opposing
tensions. See GAIL T. FAIRHURST & LINDA L. PUTNAM, ORGANIZATIONS AS DISCURSIVE
CONSTRUCTIONS 5-26 (2004); see also LESLIE A. BAXTER & BARBARA M. MONTGOMERY, A GUIDE TO
DIALECTICAL APPROACHES TO STUDYING PERSONAL RELATIONSHIPS (1998).
3
Genzyme, Who We Are, http://www.genzyme.com/corp/structure/corp_home.asp (last visited
Apr. 8, 2011).
4
Cerezyme is an enzyme replacement therapy for the treatment of Type 1 Gaucher Disease. See
Cerezyme, About Gaucher Disease, http://www.cerezyme.com/patient/treatment/cz_pt_treatment.asp
(last visited May 17, 2011). Gaucher disease is an inherited disorder that is caused by a deficiency in an
enzyme called glucocerebrosidase that occurs in approximately 1 in 50,000 live births most often
among persons of Ashkenazi Jewish heritage. Id. Symptoms include an enlarged liver and grossly
enlarged spleen. Id. The spleen can rupture and cause additional problems. Id. Skeletal weakness and
bone disease may be extensive. Id. Those who suffer from Gaucher Disease tend to bruise easily and
experience fatigue due to low numbers of red blood cells. Id. Cerezyme combats the disease by acting
like the naturally occurring enzyme to break down the fat molecules that have accumulated in Gaucher
cells. See Cerezyme, About Gaucher Disease, http://www.cerezyme.com/patient/treatment/cz_pt_treat
ment.asp (last visited May 17, 2011).
5
See, e.g., MARCIA ANGELL, THE TRUTH ABOUT DRUG COMPANIES: HOW THEY DECEIVE US AND
WHAT TO DO ABOUT IT (2010).
6
Because the production of new drugs is expensive, only a few companies demonstrate long-term
success and endurance in the industry.
7
See, e.g., Kaiser Education, Background of Prescription Drug Costs, http://www.kaiseredu.org
/Issue-Modules/Prescription-Drug-Costs/Background-Brief.aspx (last visited Apr. 10, 2011).
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high research and development costs involved in creating new drugs.8 This
reasoning is based on one of the basic economic principles: high risk can translate
into high returns. Indeed, there are high costs and risks associated with new drug
research and development.9 Not only is development of a new drug costly and
time consuming, but only a few of the new drugs make it to the pharmacy
shelves.10 Moreover, drug companies are faced with the worry of direct
competitors and substitutable products getting to the market. An additional
challenge is the looming threat of product liability lawsuits11 that could drain
millions from the corporate bank accounts.
Friedman economists12 argue that the main responsibility of businesses and
their agents is to increase profits.13 They claim that those who fail to price their
products in a way that will maximize profits are breaching their fiduciary duty to
stockholders.14 According to these proponents, the right approach or strategy is to
charge the highest price that the market will accept.15 However, the problem with
this theory is that charging maximum prices can create a false sense of scarcity of
the product which sometimes may force the government to intervene and regulate
drug prices.16
Ironically, government intervention not only fails to create a fair distribution
of the drugs, but sometimes it can exacerbate the problem.17 The price ceiling that
the government may create is usually determined by calculating the industry-wide
average cost.18 This ceiling then slowly forces the inefficient or smaller firms out,
as they are unable to make a profit from the lower price.19 Competition narrows as

8

ANGELL, supra note 5 (discussing the costs of production and research and development).
Id.
10
Id.
11
“Products liability refers to the liability of any or all parties along the chain of manufacture of
any product for damages caused by that product.” Cornell University Law School, Legal Information
Institute: Products Liability, http://topics.law.cornell.edu/wex/Products_liability (last visited Apr. 11,
2011).
12
Followers of Milton Friedman believe that free markets are the key to economic success. From
bench to bedside, THE ECONOMIST, June 28, 2007, available at http://www.economist.com/
node/9409108.
13
Ashok Gupta, Why Should Companies Care?, 18 MID-ATLANTIC J. BUS. 3 (2003), http://www.
bsu.edu/mcobwin/majb/uploads/pdf/vol18num1/03editorial.pdf.
14
Id.
15
Id.
16
John Quelch, How to Profit from Scarcity, HARVARD BUS. SCH. WORKING KNOWLEDGE (2007),
available at http://hbswk.hbs.edu/item/5776.html.
17
Hugh Rockoff, Price Controls, in CONCISE ENCYCLOPEDIA OF ECONOMICS (2008), available at
http://www.econlib.org/library/Enc/PriceControls.html.
18
R. GLENN HUBBARD & ANTHONY PATRICK O’BRIEN, MICROECONOMICS ch. 4 (2010) (Price
ceilings are determined by finding an equilibrium between producer and consumer surplus. The
government does this by averaging the prices of the particular product over an industry.).
19
This is because, as mentioned previously, while drug companies do charge prices higher than
necessary to cover costs, drug companies also have extremely high costs associated with R&D. Even
though many companies will charge more than necessary, some companies won’t charge quite as much,
setting a lower average. If the industry-wide average cost cuts below what a pharmaceutical company
needs to breakeven, the company goes out of business. Inefficient companies with higher operating
costs are the most likely to fail because, by definition, they have not lowered the costs as much as
efficient firms, and, thus, have higher operating costs.
9
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these firms withdraw from the market, and, in the long run, fewer firms may lead
back to higher prices.20 Thus, paradoxically, a governmental regulatory system
may actually in time lead back to high, unaffordable prices for consumers who
require these products.
In addition to the economic consideration that unreasonable prices may cause
problems and drive some customers away, there are ethical concerns with
companies setting too high prices. By setting prices higher than it is necessary to
make a reasonable profit, pharmaceutical companies fail to take into account the
social impact of their financial decisions. The refusal to take non-economic, social
criteria into account when pricing drugs has moral implications that can affect
large numbers of patients. It should be understood that a pharmaceutical
company’s concern for social impact and consumer equality does not mean that
they will hand out their drugs for free or sell them at such low prices that they
sustain a loss and are forced to exit the market. Fair dealing and economic
sustainability are not mutually exclusive. In fact, it is in everyone’s best interest
for drug companies to continue to research and develop new medicine and
procedures. Since research and development are funded in large part by the profits
from drugs on the market, it becomes imperative that drug companies are indeed
profitable. The tug of war between fairness and profits must be balanced just as
the economic and non-economic interests are.
The ideal outcome is to have pharmaceutical companies and consumers
interlocked in a mutually beneficial relationship. Mutually beneficial relationships
are created when value is exchanged for value. In this case, in exchange for
reasonable profits received on their goods, companies will give back some created
value to the consumer by pricing the drugs fairly and affordably. Drugs like
Cerezyme that are a life necessity for some patients can only convey value if they
are offered to those who need them at prices they can afford. When companies
view pricing formulae in this light, perhaps they will understand that unreasonable
prices are both a social issue and also a vital business concern. Moral and ethical
decision-making needs to accompany drug pricing issues. Lives of patients and
goodwill of the public are influenced by the top-level corporate decisions
pertaining to profit margins.
OVERVIEW OF GENZYME CASE STUDY
My students agree that the subject of business ethics is important and needs
to be moved to the forefront of discussion on the corporate climate marred by the
meltdown of flagship businesses21 and financial institutions22 in the United States
and abroad. Due to globalization, unethical machinations for a business in one

20
Lowering supply, while keeping the demand the same, leads to an increase in prices. See
generally HUBBARD & O’BRIEN, supra note 18.
21
Forbes, Corporate Scandal Sheet, http://www.forbes.com/2002/07/25/accountingtracker.html
(last visited May 17, 2011) (listing, for example, Enron, WorldCom, Tyco, Arthur Anderson, Satyam,
and Parmalat).
22
Wall Street Journal, Tracking the Nation’s Bank Failures, http://graphicsweb.wsj.com/documents
/Failed-US-Banks.html (last visited May 17, 2011) (listing, for example, Fannie Mae, Freddie Mac,
AIG, Lehman Brothers, Merrill Lynch, Bernard L. Madoff, and Investment Securities, LLC).
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country will ripple and affect investors and other businesses across the world.
A case in point is Stanford International Bank’s (“SIB”) collapse due to its
CEO’s multi-billion dollar scheme centering on an eight billion dollar CD
program.23 Mr. Rose Romero, Regional Director of the SEC’s Fort Worth, Texas,
Regional Office, commented that the shocking magnitude of the fraud committed
at SIB “has spread its tentacles throughout the world” as it affected and implicated
many diverse players.24 Business ethics has moral and economic dimensions that
are reflected globally.
According to various investigative reports in the UK, for example, corporate
fraud is estimated to cost the economy billions of dollars in losses.25 Unethical
business practices take many forms but typically include “overstating profits,
establishing complex accounting schemes that involve siphoning money into
offshore accounts, money laundering” and complex maneuverings by top
executives to protect dealers who trade in derivatives or equities.26
In our conversations, my students and I are reminded that seldom do
corporate executives set out to be malevolent in their business dealings.27 Rather,
it is the accumulation of small poor decisions and weakness in the face of
circumstantial pressures that force executives to make unethical decisions. Our
challenge, therefore, is to figure out how to avoid or stop the cumulative stream of
bad choices so as to immunize ourselves in the face of these contextual pressures.
The approach that we adopt in covering the topic of business ethics is based
on the dialogic, Socratic method of teaching. The students are encouraged to
accept the assumption that success in the marketplace is not an end in itself but a
means to a greater end.28 Beyond encouraging my audience to accept this
assumption, I do not “preach” to my students and do not supply them with simple
or direct answers on the topic of ethics. The case studies that we use in the
classroom (i.e. Genzyme) present organizational facts, media reports, and sets of
ethical questions that internal actors or external observers would ask. The students
are encouraged to wrestle with the case studies and find the answers to these
questions on their own.
Before we tackle the Genzyme case study, I equip the students with various
tools for analysis. One of the theories that students seem to appreciate and favor is
23
Robert Watts, FBI sweeps into cricket boss Sir Allen Stanford’s Bank, SUNDAY TIMES (UK), Feb.
15, 2009, available at http://www.timesonline.co.uk/tol/news/world/us_and_americas/article5734080
.ece.
24
See Press Release, Securities and Exchange Commission, SEC Charges R. Allen Stanford,
Stanford International Bank for Multi-Billion Dollar Investment Scheme (Feb. 17, 2009) (available at
http://www.sec.gov/news/press/2009/2009-26.htm).
25
See Counting the Cost of UK Fraud, BBC NEWS, Nov. 24, 2005, available at http://news.bbc.co.
uk/2/hi/business/4463132.stm. See also Nicola Woolcock, Cost of Fraud Spirals to £40bn, TIMES
ONLINE (UK), available at http://www.timesonline.co.uk/tol/news/uk/article633540.ece.
26
See Richard Wachman, Corporate Fraud Loses UK Business £40bn Each Year, OBSERVER, Nov.
20, 2005, available at http://www.guardian.co.uk/business/2005/nov/20/corporatefraud.observer
business.
27
See JOHN DALLA COSTA, THE ETHICAL IMPERATIVE: WHY MORAL LEADERSHIP IS GOOD
BUSINESS (1998); see also Robert Prentice, Teaching Ethics, Heuristics, and Biases, 1 J. BUS. ETHICS
EDUC. 57 (2004).
28
Examples of greater ends include social responsibility to multiple stakeholders, problem solving
in the marketplace, and solution providing for customers.
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the dialectical theory which provides the framework and vocabulary for observing,
discussing, unpacking, and analyzing the complex aspects of our ethics case
studies.
THE DIALECTICAL THEORY
The dialectical theory deals with the interplay of opposites.29 One of the
driving questions for ethics case studies is the distinction in business praxis
between the opposites of right versus wrong and good versus evil. As such the
dialectical theory lends itself well to investigating ethical conundrums pertaining to
opposing poles.
Pricing of pharmaceutical drugs is an important issue in terms of ethical
conundrums pertaining to financially challenged, underinsured, or non-insured
individuals. Moreover, it is a timely matter given the increased connectivity
among people and institutions on a global scale. A pharmaceutical company that
specializes in drugs for rare diseases, such as Genzyme, will inevitably be caught
in the tug-of-war between short-term versus long-term orientation30 and internal
versus external organizational focus.31
The Dialectical Theory Tenets and Management Strategies
Adopting an organizational dynamics angle, dialectics can be defined as the
interplay of opposites32 which lead to opportunities for change in organizational
processes.33 According to Gail Fairhurst, Linda Putnam and Karen Tracy,
dialectics is an approach well-suited for organizations because discursive processes
constitute and evolve from dialectical tensions, ones “characterized by
multivocality and the indeterminacy inherent when those multiple voices
interpenetrate.”34 This plurality of colliding and converging voices is rooted in
Bakhtin’s theory of dialectics.35
The constant presence of the organizational dialectical tension of coming
together and moving apart constitutes the first of the four tenets in dialectics:
dialectical tensions, praxis, change, and totality.36 Traditionally, dialectical
typologies that emerge from the organizational communication literature include

29

See FAIRHURST & PUTNAM, supra note 2; see also BAXTER & MONTGOMERY, supra note 2.
The struggle between short-term and long-term orientation is seen in the areas of profitability and
financial sustainability.
31
This struggle is between the external shareholders and the company’s internal bottom line.
32
See BAXTER & MONTGOMERY, supra note 2.
33
I use the term dialectics and not dualism, duality, or dichotomies, since these other terms do not
necessarily point to existing tension, although it could exist. In other words, dual elements can co-exist
without leading to friction or triggering change. On the other hand, dialectics, by its very definition,
implies and assumes the presence of opposites in dynamic tension that affect the status quo. A
subsequent section of the study presents a typology of dialectics.
34
See BAXTER & MONTGOMERY, supra note 2; see also KAREN TRACY, EVERYDAY TALK:
BUILDING AND REFLECTING REALITIES (2002); see also LESLIE A. BAXTER, RELATIONSHIPS AS
DIALOGUES 2 (2004).
35
See MIKHAIL BAKHTIN, SPEECH GENRES AND OTHER LATE ESSAYS (1986).
36
See BAXTER & MONTGOMERY, supra note 2.
30
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integration/ separation, stability/change, open/closed, freedom/control, and
certainty/uncertainty.37
Baxter describes these dialectical tensions as the
interpenetration of united and opposed discourses which actors negotiate in their
discursive interactions.38 This point is further developed by Baxter’s claim that
dialectics cannot exist separate of communication and action.39 The dialectical
tensions that actors experience in their discursive practices are instrumental in
making and sharing meaning. Actors relate to selves and others in terms of the
meaning that emerges from managing these dialectical tensions. This active
management of dialectical tensions leads us to the next tenet, the concept of
praxis.
Praxis40 is based on the assumption that individuals are choice-making,
action-oriented agents in their organizations. As such, individuals are proactive, in
control, and enabled by their past actions and discourses. However, organizations
and social worlds also act back on these individuals.41 Thus, individuals can
become reactive and limited by their prior actions and discourses. To that end,
praxis centers on the idea that actors will oscillate between two experiences:
subject (proactive, choice-making, acting on) and object (reactive, choiceconstrained, being acted upon). Along this continuum there are choice-points that
actors can embrace when managing dialectics.
Seo, Putnam, and Bartunek discuss five specific choice points that actors can
engage when managing dialectical tensions: selection, separation, integration,
transcendence, and connection.42 First, selection entails denial; actors place the
two poles in a “cold war” relationship where they ignore one of the poles and favor
the other. Second, separation allows for the existence of both opposing poles, but
places them in a pendulum-like oscillation movement; both dialectical poles exist
but they are separated “through levels of analysis, topical domains, or temporal
processes.”43 The third pattern of praxis, integration, combines the dialectical
tensions in neutralizing or bridging ways. This is reminiscent of the Hegelian
synthesis that brings about a new state which contains diluted residues of the two
previous antithetical states. Fourth, transcendence manages the tensions by
abandoning them and reformulating a new whole. The two poles are downplayed
37
See Linda L. Putnam, Dialectical Tensions and Rhetorical Tropes in Negotiations, 25 ORG.
STUD. 35 (2004).
38
See Leslie A. Baxter, Relational Dialectics Theory: Multivocal Dialogues of Family
Communication, in ENGAGING THEORIES IN FAMILY COMMUNICATION: MULTIPLE PERSPECTIVES 130
(2006).
39
See id.
40
MERRIAM-WEBSTER DICTIONARY (2011), available at http://www.merriam-webster.com
/dictionary/praxis (defining praxis as translating an idea into action. It is thought of as the application
or use of knowledge or skills.).
41
See KAREN TRACY, EVERYDAY TALK: BUILDING AND REFLECTING IDENTITIES (Guilford Press
2002).
42
See Myeong Seo, Linda Putnam, & J.M. Bartunek, Dualities and Tensions of Planned
Organizational Change, in HANDBOOK OF ORGANIZATIONAL CHANGE AND INNOVATION (2004); see
also LESLIE A. BAXTER & BARBARA M. MONTGOMERY, RELATING: DIALOGUES AND DIALECTICS
(Guilford Press 1996). Baxter and Montgomery present eight patterns of praxis for managing
dialectical tensions: denial, disorientation, spiraling inversion, segmentation, balance, integration,
recalibration, and reaffirmation. Id.
43
See id.
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or transformed through reframing which shifts the actors’ attention to new
meanings. Finally, connection seeks to find ways to equally accept the dialectical
tensions by giving them “equal voice.” The difference between the opposing poles
is maintained while “the two poles are connected to each other in a synergistic
manner where they become mutually beneficial.”44 Seo’s article provides a
framework and a vocabulary for discussing the discursive strategies that actors
embrace when dealing with change-inducing dialectical tensions.45
Next, change constitutes the third tenet of the dialectical theory. Change
refers to the procedural and patterned difference in a phenomenon over a period of
time.46
Organizational change (i.e. leadership succession) is a complex
phenomenon that can be heuristically explained through the analysis of the
dialectical tensions present in the discursive interactions of actors. This concept
embraces Fairhurst and Putnam’s becoming orientation for organizations.47
Organizations are in a constant state of change. The complexity of conflicting
discourses in an organization shape and re-shape the organization and its
processes.48
Finally, totality refers to the notion that sets of dialectics cannot be fully
understood in isolation from each other and in separation from context.
Organizations are best viewed as systems of interdependencies and
interrelatedness. Sets of dialectics work together and define each other.49 Thus,
multiple levels of organizations exhibit multiple sets of embedded and coformative dialectics.
Employing the dialectical theory for case study analysis is both intentional
and strategic. The dialectical theory provides the tools and vocabulary to
conceptualize and unpack the ethical tensions experienced and enacted by key
organizational actors and the organizations themselves as a whole.

44
See Kevin Barge et al., Managing Dualities in Planned Change Initiatives, 36 J. APPLIED COMM.
RES. 364 (2008).
45
See Seo et al., supra note 42.
46
See BAXTER & MONTGOMERY, supra note 2; see also Marshall S. Poole & Andrew H. Van de
Ven, Theories of Organizational Change and Innovation Processes, in HANDBOOK OF
ORGANIZATIONAL CHANGE AND INNOVATION (Oxford Univ. Press 2004). Poole and Van de Ven
remark that there are four types of change theories: teleological, life cycle, evolutionary, and dialectical.
Id. The authors state that change can be often the response to a dialectical motor that deals with
tensions around an organizational unit. Id.
47
See FAIRHURST & PUTNAM, supra note 2.
48
BAKHTIN, supra note 35. Bakhtin points to the fact that dialogue is not able to be finalized due
to the never-ending interaction between what he calls the centripetal and centrifugal forces that shape
society (or relationships and organizations). Id. Bakhtin remarks that the constant friction between
voices of unity and voices of separation brings about change in societal (and organizational) systems.
Id. He visualizes these voices as forces of coming together and pulling apart. Id. These voices or
forces are constantly present and reflected in the discursive interactions of actors at macro (society),
meso (organizations), and micro (groups and dyadic relationships) levels. Id. As key actors negotiate
discursively the management of organizational dialectics (i.e. long-term vs. short-term orientations or
internal vs. external concerns), the organization itself changes. Id.
49
See BAXTER & MONTGOMERY, supra note 42.
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Dialectics Typology50
There are sets of dialectical tensions that some organizational actors of
organizations might experience at times. They generally tend to center around
three categories: relational, organizational, and goal-orientation. The typology of
these sets and the push-pull tension and interplay of opposites can help us better
understand actors’ motivation and intention when dealing with various situations.51
GENZYME
The focus of the case study is Genzyme; a successful biotechnology
company based in Boston, Massachusetts.52 First, the company is described using
the material offered on its website.53 Second, various media reports are introduced
to highlight key aspects pertinent to the case study. Next, the ethical quandary is
introduced. Finally, questions for discussions are supplied as informed by the
dialectical theory and the case study material.
Background Information
One of the world’s foremost biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people with serious
diseases.54 Founded in Boston in 1981, Genzyme has grown from a small start-up
to a diversified enterprise with annual revenues exceeding $3 billion and 10,000
employees in locations spanning the globe.55
The company has delivered consistent financial results, with a compound
annual growth rate in excess of twenty percent over the past five years. In 2007,
Genzyme was chosen to receive the National Medal of Technology, the highest
honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly
ninety countries, Genzyme is a leader in the effort to develop and apply the most
50
See Conference of the International Communication Association, Andrei C. Duta, Meta-level
Dialectical Interpenetrations in Transformational and Charismatic Leadership (2009).
51
See id. The dialectical tensions are categorized as follows: Relational, 1. Freedom and Control
(a. Chaos and Order, b. Non-routine and Routine, c. Change and Stability, d. Risk and
Conservativeness, e. Formality and Collegiality), 2. Emotional and Rational (a. Relationship and Task,
b. Heart and Head, c. High-touch and High-tech, d. EQ and IQ), 3. Trust and Distrust (a. Unity and
Division, b. Cooperation and Competition, c. Team and Collective, d. Identification and Differentiation,
e. Incentives and Threats, f. Dependence and Independence), 4. Informal and Formal, 5. Public and
Private, 6. Clarity and Ambiguity (Certainty and Uncertainty); Organizational Roles, 1. Universal and
Situational (a. Informal and Formal, b. Public and Private, c. Emotional and Rational), 2. Internal and
External, 3. Task and Relationship, 4. Giving power and Gaining Power, 5. Risk and Conservative (a.
Bricoleur and Traditionalist, b. Non-routine and Routine), 6. Reflexive-based and Praxis-based (Being
and Doing); Goals, 1. Budget-focus and Customer-focus (a. Cost-focus and Revenue-focus, b. Core
purposes and Creative vision), 2. Long-term and Short-term, 3. Centralized and Decentralized
(Hierarchical view and Horizontal view), 4. Global Goals and Short Term Goals and Emergent Goals.
Id.
52
See Genzyme, supra note 3.
53
See id.
54
See id.
55
See id.
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advanced technologies in the life sciences.56 Genzyme develops, manufactures
and markets a range of innovative health care products and services that make a
major positive impact on the lives of patients around the world. The company’s
products and services are focused on rare inherited disorders, kidney disease,
orthopedics, transplants, cancer, and diagnostic testing. Genzyme’s commitment
to innovation continues today with a substantial research and development
program focused on these fields, as well as immune disease, infectious disease, and
other areas of unmet medical need. The company’s headquarters are in
Cambridge, Massachusetts, in the United States.57
Organizational Leadership: Twenty-Four Executive Officers and Eight
Board Members.58
Henri A. Termeer
Henri A. Termeer was appointed President of Genzyme Corporation in 1983, two
years after the company’s founding. He became its Chief Executive Officer in 1985
and Chairman in 1988. Under his leadership, Genzyme has grown to be an
international leader in the biotechnology industry.
Mr. Termeer is recognized as a pioneer in developing and delivering treatments to
patients with rare genetic diseases around the world. This work has provided the
foundation for Genzyme’s success, and today the company is diversified across
several medical areas.
Widely acknowledged for his contributions to the biotechnology industry and
health care field, Mr. Termeer is active in the areas of humanitarian assistance,
policy issues, and innovation in providing access to health care. He serves on the
board of directors of both the Biotechnology Industry Organization and the
Pharmaceutical Research and Manufacturers of America. He is a director of
Massachusetts General Hospital and is a member of the board of fellows of Harvard
Medical School.59

Media Reports60
Genzyme Delivers Strong Third-Quarter Sales and Earnings Growth
(10-22-08)61
Genzyme Corporation (NASDAQ: GENZ) announced today that third-quarter
revenue rose 21 percent [sic] to $1.160 billion, compared with revenue of $960.2
million in the same period a year ago. The increase was driven by double-digit
growth in every Genzyme business unit.

56

See id.
See Genzyme, supra note 3.
58
See id.
59
See Genzyme, Corporate Officers: Henri A. Termeer, www.genzyme.com/corp/structure/bios_
termeer.asp#P25_486 (last visited May 17, 2011).
60
See Genzyme, Investor Information, www.genzyme.com/corp/investors/inv_home.asp (last
visited May 17, 2011).
61
Id.
57
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Generally Accepted Accounting Principles (GAAP) net income was $119.6 million,
or $0.42 per diluted share, compared with $159.3 million, or $0.58 per diluted
share, in last year’s third quarter. Net income in 2008’s third quarter reflects a $100
million licensing fee for rights to PTC124, a promising genetic disease drug in latestage development.62
During the third quarter, Genzyme generated approximately $481 million in cash
from net income prior to one-time events and proceeds from the issuance of
common stock. The company has increased its cash position to approximately $1.5
billion while making investments to support long-term growth, including
investments to expand manufacturing capacity, to offset dilution by repurchasing
shares, and to complete strategic transactions that strengthen its late-stage
pipeline.63

“The third quarter was a very strong quarter financially and also extremely
productive in terms of building for the future,” said Henri A. Termeer, chairman
and chief executive officer of Genzyme Corp. “Our broad geographic
diversification, solid cash position, and group of market-leading products will
allow us to sustain our growth through the current financial environment and over
the longer term.”64
Genzyme is on track to meet its goal of 20% compound average non-GAAP
earnings growth from 2006 through 2011. For 2009, the company expects nonGAAP earnings to increase to approximately $4.70 per diluted share. Non-GAAP
earnings are projected to rise to approximately $7.00 per diluted share by 2011.65
These estimates include the impact of Genzyme’s redemption of its
convertible senior notes. The company plans to redeem all $690 million of these
notes as of December 1, 2008. The notes are redeemable in cash or can be
converted to common stock at the option of the noteholders at a conversion price
of $71.24 per share.66
Genzyme Expands its Research and Manufacturing Presence in
Massachusetts
Genzyme announced the start of construction on an innovative new science
building that is a signature component of a $210 million investment the company is
making in its Massachusetts research and manufacturing operations. This includes a
new research facility in Waltham and a major expansion of the company’s flagship
protein manufacturing facility in Allston.67

62

Id.
Id.
64
See Genzyme Reports Strong Third Quarter Sales and Earnings Growth, WORLD PHARMA
NEWS, Oct. 24, 2008, available at http://www.worldpharmanews.com/genzyme/577-genzyme-reportsstrong-third-quarter-sales-and-earnings-growth.
65
See Press Release, Genzyme, Genzyme Reports Strong Fourth Quarter and 2008 Revenue
Growth (Jan. 13, 2009) (available at http://www.genzyme.com/corp/investors/GENZ%20PR011309.asp).
66
See id.
67
See Manufacturing at Genzyme’s Allston Landing Facility, http://www.genzyme.com/corp/
careers/Allston_Manufacturing.pdf (last visited May 17, 2011).
63
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Genzyme Recognized by Scientists as a Top Employer for Third
Consecutive Year
Scientists have again named Genzyme Corporation a top employer in a 2005 survey
ranking the reputations of biotechnology and pharmaceutical companies. Genzyme
placed sixth among the 459 global companies included in the survey and is the
highest ranked company in New England.68

Genzyme Named One of the Best Employers in the World
Genzyme was named one of the “250 Best Places to Work” in Portugal,
February 2008.69
ETHICAL DILEMMA
On November 16th, 2005, the Wall Street Journal featured a special article on
Genzyme. The article discussed one of Genzyme’s flagship drugs, Cerezyme, and
the drug’s low level of affordability for some of the customers/patients against the
backdrop of the company’s strong financial situation. One of the central issues
presented in the article was the fairness of charging the patients too much for the
drug.70
Geeta Anand’s article triggered a large number of conversations on the topic
of Genzyme and Cerezyme.71
CASE STUDY KEY POINTS72
Gaucher disease: frailty of the bones, deformity of the joints, deterioration of
the bones, a cruel disease.
Cerezyme drug is used to fight Gaucher disease.
Average cost is $200,000 a year per patient.
Company makes 90% gross profit margin on Cerezyme.
Cerezyme generated a billion dollars in revenue in 2006.
Carol, patient: $601,000 a year for treatment ($520,000 for Cerezyme and
$81,000 for nurse).
Only 4,000 patients in the world who deal with the Gaucher disease.
Mr. Henri Termeer, CEO: $3,000,000 salary/bonus last year plus options
values of $12.6 to $32 million in ten years based on company’s stock appreciation

68
See Genzyme, Awards and Recognition, http://www.genzyme.com/corp/structure/awards/awards
_2006_earlier.asp (last visited May 17, 2011).
69
See Genzyme, Genzyme in the News, http://www.genzyme.com/corp/media/inthenews_genz.asp
(last visited May 17, 2011).
70
See Geeta Anand, A Biotech Drug Extends a Life, But at What Price?, WALL ST. J. (Nov. 16,
2005), available at http://online.wsj.com/article/SB113210858490898540.html.
71
See Wall Street Journal Examines Higher Price of Gaucher Disease Treatment Cerezyme, MED.
NEWS TODAY (Nov. 17, 2005), available at www.medicalnewstoday.com/articles/33642.php; see also
Economics, Politics, and Psychology: The Case of Avian Flu—Posner, The Becker-Posner Blog,
http://www.becker-posner-blog.com/archives/2005/11/ (Nov. 15, 2005).
72
See Anand, supra note 70.

DUTA_FORMAT_FINAL.DOCX (DO NOT DELETE)

2011

GENZYME’S ETHICAL DILEMMA

4/18/2012 5:58 PM

519

(as of 2005).
The company claims that a substantial part of the profits sponsors the drug in
poor countries and funds new research for other rare diseases.
DISCUSSION QUESTIONS
Is it ethical to generate a 90% gross profit margin on a medical drug such as
Cerezyme? Is this even an ethical matter?
Some parties would consider that this is an ethical matter. Since the high
profit margin on Cerezyme makes the drug unaffordable for some patients, fiscal
concerns turn into moral concerns in this situation. While it can be argued that
managers of pharmaceutical companies have no ethical responsibility in regards to
pricing strategies and that their only responsibility is to maximize profits,
Genzyme must realize that the most profitable business is one of long-term
orientation that seeks to satisfy both the expectations of shareholders as well as the
interests of patients.
How does the dialectical theory apply to the ethics dilemma at Genzyme?73
The dialectical theory applies to the case study because the decisions that
Genzyme must make regarding their profit margins and pricing strategies emerge
from the management of dialectics or underlying opposing tensions. Potential
dialectics present in this case study include: purposing versus functioning, shortterm versus long-term, change versus stability, competing versus cooperating,
public versus private, internal versus external, budget-focused versus customerfocused, and systemic or meta-level dialectics of freedom versus control and freemarket versus centralized economy.
Some of these dialectics revolve around Genzyme’s arguments in favor of
high margins and the corresponding counterarguments or counter questions:
It took us a long time to recover initial R&D costs to break even.
What is the exact timeline for breaking even? What is reasonable in light of
the fact that there is no competition to drive the prices down?
We are using part of the profits to research new rare diseases and create new
drugs to help more people.
Should the US patients be forced to cover these costs? Would it be fairer to
have government grants cover these R&D costs? How about minimizing company
profits while still channeling internal resources to R&D? Are there tax benefits for
this? Could general goodwill with the public and the company’s corporate social
responsibility reputation function as an incentive to lower the drug prices?
We are donating the drug to people in third world countries who could not
afford it otherwise.
Should US patients be the forced to subsidize the drug for patients in
developing countries?

73
What dialectics or push-pull tensions are present in this situation? What voices are present in the
debate? What contradictions? What conflicts? What management strategies are or should be
employed in dealing with these dialectics?
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Who are the stakeholders in this case? What parties are affected by Genzyme
and its drug pricing policies?
Potential stakeholders include: government agencies, competition, private
citizens, CEO, other executive officers, board of directors members, staff, media,
patients, patients with or without insurance, patients in third world countries,
insurance companies, doctors, shareholders in the company, company employees
with stock options, company employees without stock options, lawyers, and
government policy makers.
What is the role of the board of directors?
The role of the board of directors includes exercising fiduciary duty owed to
shareholders, providing accountability for management, strategically setting the
course for financial profitability, fulfilling purpose versus function roles for the
organization, encouraging corporate social responsibility, and setting the moral
direction for the company and its executive leadership.
Is it problematic that Mr. Termeer assumes a dual role (CEO and board
chair) position at Genzyme?
Since Mr. Termeer serves as both CEO and Chairman of the Board, he deals
with potential conflicting interests. Issues of independence and objectivity could
arise in this instance. Mr. Termeer’s conflicting roles (purposing roles as Chair
and board member and functioning role as CEO) could create problems. There is
concern that serving in this dual role could lead to a conflict of interest between
Mr. Termer’s personal goals and the goals of the company. The potential conflict
of interest problems could be avoided with either the separation of the roles or the
appointment of a lead director.
What other questions should be asked in light of the dialectical theory and
Genzyme?
CONCLUSION
The dialectical theory has heuristic value as it greatly aids in the process of
knowledge creation when it comes to unpacking and understanding ethical
predicaments. The theory is relatively easy to understand once the students get
over the more abstract Bakhtinian concepts.
Accuracy is high as the dialectical theory can detect, describe, and
understand the sets of ethical tensions that various internal actors and relevant,
external stakeholders may experience in various organizational contexts as the
Genzyme case study demonstrates.
The main critique of the dialectical theory is its non-generalizability (from
case study to case study) and its potential “self-fulfilling prophesy” approach. The
dialectical theory functions as both theory and method of analysis. Ontologically,
the dialectical theory is leveraged as a prism through whose lenses the students can
view organizations and their actors’ struggles with ethical dilemmas.
Epistemologically, the dialectical theory functions as a method for analysis and
knowledge creation. As such, the student can become self-biased and end up
observing conflicts, tensions, and contradictions even in situations where they may
be absent.
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However, the primary strengths of the dialectical theory far outweigh its
weaknesses of limited generalizability and self-prophecy tendencies. Perhaps the
greatest contribution of the dialectical theory is the fact that it examines
organizations from a systemic perspective that seeks to embrace the whole. The
theory is effective in illuminating various ethical challenges that emerge in larger
organizational contexts, as is the case with Genzyme.
Finally, the theory is useful since it provides the springboard for meaningful
student-led conversations about relevant ethical dilemmas in corporate America.
The ultimate goal is to have the students engage in deep cogitative and
communicative processes regarding the difference between “right versus wrong”
and “good versus evil.” Hopefully, the dialectical theory provides the seeds for
future virtuous conversations that will take place long after the students have
graduated and have entered the marketplace.

